TrailBio™ Pre-Myelinating Oligodendrocyte Kit
TrailBio™ Pre-Myelinating Oligodendrocytes are highly characterized cells that resemble a pre-myelinating oligodendrocyte state. These cells enable the screening of compounds that modulate myelination, supporting drug development for neurodegenerative and demyelinating diseases, such as multiple sclerosis.
TrailBio™ Pre-Myelinating Oligodendrocytes are naturally differentiated from human iPSC using HD-DoE™ technology platform, meaning scalability is built-in.
Upon thawing (day 1), cells are ready for experimentation and express the oligodendroglial lineage marker O4. By simply maintaining cells in a monolayer culture, cells rapidly mature and acquire a typical oligodendrocyte-like morphology with multiple branched processes. Cells start expressing oligodendrocyte markers, including MBP, OLIG2, SOX10, and NKX2-2.
- Vial Size: 5 x 10⁶ viable cells
- Price: $2,000 per vial ($400 per million cells)
- Kit Includes: Cells, Media, RNA-Seq Data, Safety Datasheet, Supplement
Product Information
Starting Material: Human iPSCs
Format: Cryopreserved single cells
Donor Information: Male
Karyotype: Normal
Source Cell: CD34+ cord blood
Shipping info: Dry ice
Quality Control: Sterility, bulk RNA-seq, flow cytometry, qPCR, ICC
Differentiation method: Stepwise Differentiation
Seeding Compatibility: 6 to 96 well-plates
User Storage: LN2
Recommended seeding density: 150,000 cells/cm2
Protocol use: TrailBio™ cells are for research use only
The Trailhead Advantage
Defined
Human O4+ cells initially display a typical OPC-like morphology. They mature into oligodendrocyte-like cells that have multiple branched processes.
Non-Edited
These cells maintain their unmodified genome as they are naturally differentiated into the pre-myelinating oligodendrocyte state.
Easy to use
Cryopreserved cells arrive ready to be used upon revival. Simple monolayer culture protocol.
Immunocytochemistry
Immunofluorescent staining at day 14 post-revival demonstrates the increasing complexity of TrailBio™ Pre-Myelinating Oligodendrocytes as they mature in culture. The cells are positive for the oligodendrocyte lineage marker O4 (green) as well as the myelin basic protein MBP (red), indicating they are acquiring the characteristic protein expression profile of pre-myelinating oligodendrocytes. The staining reveals the elaborate branched morphology the cells develop by 14 days after thawing.
Morphology
Highly branched morphology of TrailBio™ Pre-Myelinating Oligodendrocytes 14 days after thawing. The OPCs have developed extensive intricate networks of fine membrane extensions, characteristic of cells progressing towards the pre-myelinating stage. This complex branching pattern indicates the cells are nearing maturity and preparing to initiate myelination.
Scale bar: 100 μm.
Key Genes and Markers
The data demonstrates that upon differentiation, TrailBio™ Pre-Myelinating Oligodendrocytes robustly express multiple key markers characteristic of the oligodendroglial lineage. At day 1 post-revival, the cells already show expression of oligodendrocyte markers like ST18, SNF536, BCAN, and GPR17. By day 14, the expression levels of these relevant markers have increased substantially as the cells continue to mature along the oligodendroglial pathway. This marker analysis confirms the cells are effectively differentiating into a pre-myelinating oligodendrocyte population and acquiring the expected gene expression profile over the 14-day differentiation time course.
Custom iPSC Differentiation
Do you need differentiated cells but need to model specific diseases or require proprietary iPSC lines? Trailhead Biosystems’ Custom Differentiation Service can help!
With our Custom Differentiation Services, you can:
- Send us your disease-specific cells or iPSC lines
- Leverage our proprietary protocols for precise differentiation
- Obtain highly relevant, disease-specific cell types
Our expert team will work closely with you to develop customized cellular models that recapitulate your disease of interest.
Take your research to new heights with unparalleled access to disease-relevant cell types, meticulously differentiated to meet your unique requirements.